Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Di Giovanni, Giuseppe (University of Malta)
Svob Strac, Dubravka (Rudjer Boskovic Institute)
Sole, Montse (Universitat Autònoma de Barcelona. Institut de Neurociències)
Unzeta López, Mercedes (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Tipton, Keith F. (Trinity College Dublin)
Mück-Šeler, Dorotea (Rudjer Boskovic Institute Zagreb, Croatia)
Bolea Tomás, Irene (Universitat Autònoma de Barcelona. Institut de Neurociències)
Della Corte, Laura (Università degli Studi di Firenze)
Nikolac Perkovic, Matea (Rudjer Boskovic Institute Zagreb, Croatia)
Pivac, Nela (Rudjer Boskovic Institute Zagreb, Croatia)
Smolders, Ilse J. (Vrije Universiteit Brussels, Belgium)
Stasiak, Anna (Medical University of Lodz, Poland)
Fogel, Wieslawa A. (Medical University of Lodz, Poland)
De Deurwaerdère, Philippe (Institut of Neurodegenerative Diseases Bordeaux Cedex, France)

Data:	2016
Resum:	The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from in vivo neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable strategies for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson's disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Antipsychotic ; Antidepressant ; Monoamine oxidase inhibitor ; Multi-target pharmacology ; Neurodegenerative diseases ; Stroke ; Antiparkinsonian treatments ; Drug addiction
Publicat a:	Frontiers in Neuroscience, Vol. 10 (november 2016) , ISSN 1662-453X

DOI: 10.3389/fnins.2016.00541
PMID: 27932945

28 p, 2.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Neurociències (INc)
Articles > Articles de recerca
Articles > Articles publicats